Secondary prophylaxis after myocardial infarction, bypass surgery and percutaneous coronary intervention;Sekundærprofylakse etter hjerteinfarkt, bypasskirurgi og perkutan koronar intervensjon

Tidsskrift for den Norske Laegeforening

Volumn 124, Issue 7, 2004, Pages 946-949

  Eritsland, Jan ^a   Arnesen, Harald ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OMEGA 3 FATTY ACID; FIBRINOLYTIC AGENT; HYPOCHOLESTEROLEMIC AGENT;

ANTICOAGULANT THERAPY; BYPASS SURGERY; CARDIOVASCULAR RISK; CORONARY ARTERY ATHEROSCLEROSIS; DIET SUPPLEMENTATION; GRAFT OCCLUSION; HEART INFARCTION; HEART INFARCTION PREVENTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INTERNATIONAL STANDARD UNIT; LIFESTYLE; PERCUTANEOUS CORONARY INTERVENTION; PRESCRIPTION; REVIEW; SECONDARY PREVENTION; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; CORONARY ARTERY BYPASS GRAFT; POSTOPERATIVE CARE; RISK FACTOR; TRANSLUMINAL CORONARY ANGIOPLASTY;

ADRENERGIC BETA-ANTAGONISTS; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTICHOLESTEREMIC AGENTS; ANTICOAGULANTS; CORONARY ARTERIOSCLEROSIS; CORONARY ARTERY BYPASS; FIBRINOLYTIC AGENTS; HUMANS; LIFE STYLE; MYOCARDIAL INFARCTION; POSTOPERATIVE CARE; RISK FACTORS;

EID: 1842784972     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. Burr ML, Gilbert JF, Holliday RM, Elwood PC, Fehily AM, Rogers S et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: Diet and Reinfarction Trial (DART). Lancet 1989; 333: 757-61.
2. de Lorgeril M, Renaud S, Mamelle N, Salen P, Martin J-L, Monjaud I et al. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet 1994; 343: 1454-9.
3. Wilson K, Gibson N, Willan A, Cook D. Effect of smoking cessation on mortality after myocardial infarction. Meta-analysis of cohort studies. Arch Intern Med 2000; 160: 939-44.
4. Blood Pressure Lowering Treatment Trialists Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000; 360: 1455-61.
5. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
6. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G et al. Long-term ACE-inhibitor therapy in patients with heart failure of left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 2000; 355: 1575-81.
7. Andersen K, Hurlen M, Arnesen H, Seljeflot I. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 2003; 108: 37-42.
8. Steinhubl SR, Berger PB, Mann JT, Fry ETA, DeLago A, Wilmer C et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. JAMA 2002; 288: 2411-20.
9. van de Werf F, Ardissino D, Betriu A, Cokkinos DV, Falk E, Fox KAA et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2003; 24: 28-66.
10. Bertrand ME, Simoons ML, Fox KAA, Wallentin L, Hamm C, McFadden E et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2002; 22: 1809-40.
11. Freemantle N, Cleland J, Young P, Mason J, Harrison J. β-blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999; 318: 1730-7.
12. Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990; 323: 147-52.
13. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
14. Coumadin Aspirin Reinfarction Study (CARS) investigators. Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Lancet 1997; 350: 389-96.
15. Fiore LD, Ezekowitz MD, Brophy MT, Lu D, Sacco J, Peduzzi P et al. Department of Veterans Affairs Cooperative Studies program clinical trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study. Circulation 2002; 105: 557-63.
16. van Es RF, Jonker JJ, Verheugt FWA, Deckers JW, Grobbee DE. Asprin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet 2002; 360:109-13.
17. Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002; 347: 969-74.
18. Hurlen M, Erikssen J, Smith P, Arnesen H, Rollag A. Comparison of bleeding complications of warfarin and warfarin plus acetylsalicylic acid: a study in 3166 outpatients. J Intern Med 1994; 236: 299-304.
19. Vatne K, Kløw N-E. Kateterbehandling av koronarsykdom. Tidsskr Nor Lægeforen 1994; 114: 3441-5.
20. Eritsland J, Arnesen H, Grønseth K, Fjeld NB, Abdelnoor M. Effect of dietary supplementation with n-3 fatty acids on coronary artery bypass graft patency. Am J Cardiol 1996; 77: 31-6.